PSPaul Stoll

Paul Stoll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Stoll has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stage-dependent association of BDNF and TGF-beta1 with lung function in stable COPD

    by Paul Stoll, Urs Wuertemberger, Kai Bratke, Christiana Zingler, Christian J Virchow, Marek Lommatzsch

    Chronic Obstructive Pulmonary Disease (COPD) is characterised by complex inflammatory, neuronal and fibrotic changes. Brain-derived Neurotrophic Factor (BDNF) is a key regulator of neuronal plasticity, whereas Transforming Growth Factor-β1 (TGF-β1) plays a crucial role in tissue repair and emphysema pathogenesis. Both mediators are stored in platelets and released from platelets in inflammatory conditions and during serum preparation. In patients with asthma, it was previously shown that elevated serum BDNF concentrations correlate with disease severity, whereas TGF-β1 concentrations were normal.


  • Differential effect of clopidogrel and aspirin on the release of BDNF from platelets

    by Paul Stoll, Annett Plessow, Kai Bratke, J. Christian Virchow, Marek Lommatzsch


  • Postpartum Venous Thromboembolism

    by Paul Stoll, J. Christian Virchow, Marek Lommatzsch

    In their Image in Clinical Medicine, Zalts and Hayek (Dec. 18 issue)1 describe a woman with postpartum venous thromboembolism. The patient was found to be heterozygous for a mutation in the gene encoding for 5,10-methylenetetrahydrofolate reductase (MTHFR). The authors suggest that the mutation was most likely the source of her susceptibility to hypercoagulation. However, a recent, large-scale, prospective study involving 66,140 participants did not show an association between a homozygous or heterozygous MTHFR genotype and the risk of venous thromboembolism.2 The odds ratio for the development of venous thromboembolism was 1.01 for the heterozygous (C677CT) or homozygous (C677TT) genotype, as compared with the normal MTHFR genotype. Moreover, a heterozygous genotype was found in 41% of the population, in both the case and control groups, suggesting a much higher prevalence of the aberrant genotype than of venous thromboembolism.2 Therefore, in the patient described by Zalts and Hayek, the acquired risk factors (pregnancy and postpartum period, surgery, and reduced mobility), which were recently reviewed in the Journal, 3 appear to be a more likely cause of venous thromboembolism than the observed mutation in the gene encoding MTHFR.